| Autor: |
Taipale H; Karolinska Institutet, Department of Clinical Neuroscience, Stockholm, Sweden. heidi.taipale@ki.se.; University of Eastern Finland, School of Pharmacy, Kuopio, Finland. heidi.taipale@ki.se., Rahman S; Karolinska Institutet, Department of Clinical Neuroscience, Stockholm, Sweden., Tanskanen A; Karolinska Institutet, Department of Clinical Neuroscience, Stockholm, Sweden.; University of Eastern Finland, Department of Forensic Psychiatry, Niuvanniemi Hospital, Kuopio, Finland., Mehtälä J; EPID Research Oy, Espoo, Finland., Hoti F; EPID Research Oy, Espoo, Finland., Jedenius E; Janssen Cilag, Solna, Sweden., Enkusson D; Janssen Cilag, Solna, Sweden., Leval A; Janssen Cilag, Solna, Sweden., Sermon J; Janssen Cilag, Beerse, Belgium., Tiihonen J; Karolinska Institutet, Department of Clinical Neuroscience, Stockholm, Sweden.; University of Eastern Finland, Department of Forensic Psychiatry, Niuvanniemi Hospital, Kuopio, Finland.; Center for Psychiatry Research, Stockholm City Council, Stockholm, Sweden., Mittendorfer-Rutz E; Karolinska Institutet, Department of Clinical Neuroscience, Stockholm, Sweden. |
| Abstrakt: |
This study aimed to identify if antipsychotic exposure in offspring is associated with psychiatric and non-psychiatric healthcare service use and work disability of their parents. This Swedish population-based cohort study was based on data comprising 10,883 individuals with schizophrenia, who had at least one identifiable parent in the nationwide registers, and their parents (N = 18,215). The register-based follow-up during 2006-2013 considered the level of antipsychotic exposure and persistence of use of the offspring, further categorized into first (FG) and second generation (SG) antipsychotics, and orals versus long-acting injections (LAIs). The main outcome measure was parental psychiatric healthcare service use, secondary outcomes were non-psychiatric healthcare use and long-term sickness absence. SG-LAI use was associated with a decreased risk (relative risks [RR] 0.81-0.85) of parental psychiatric healthcare use compared with not using SG-LAI, whereas oral antipsychotics were associated with an increased risk (RRs 1.10-1.29). Both FG- and SG-LAI use by the offspring were associated with a lower risk of long-term sickness absence (range of odds ratios 0.34-0.47) for the parents, compared with non-use of these drugs. The choice of antipsychotic treatment for the offspring may have an impact on work disability and healthcare service use of their parents. |
